Penn Davis Mcfarland Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,583 shares of the biopharmaceutical company’s stock after buying an additional 215 shares during the period. Gilead Sciences accounts for approximately 4.2% of Penn Davis Mcfarland Inc.’s investment portfolio, making the stock its 10th biggest position. Penn Davis Mcfarland Inc.’s holdings in Gilead Sciences were worth $12,538,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in shares of Gilead Sciences by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 16,867,065 shares of the biopharmaceutical company’s stock valued at $1,053,332,000 after purchasing an additional 835,915 shares during the last quarter. Parnassus Investments CA increased its holdings in shares of Gilead Sciences by 21.2% in the first quarter. Parnassus Investments CA now owns 13,074,555 shares of the biopharmaceutical company’s stock valued at $849,976,000 after purchasing an additional 2,288,767 shares during the last quarter. Norges Bank acquired a new position in shares of Gilead Sciences in the fourth quarter valued at $798,882,000. Sanders Capital LLC increased its holdings in shares of Gilead Sciences by 5.0% in the first quarter. Sanders Capital LLC now owns 11,291,933 shares of the biopharmaceutical company’s stock valued at $793,701,000 after purchasing an additional 539,793 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Gilead Sciences by 6.7% in the fourth quarter. Legal & General Group Plc now owns 6,552,231 shares of the biopharmaceutical company’s stock valued at $409,842,000 after purchasing an additional 408,910 shares during the last quarter. Institutional investors and hedge funds own 78.66% of the company’s stock.

In related news, EVP Brett A. Pletcher sold 7,200 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the sale, the executive vice president now owns 34,398 shares of the company’s stock, valued at $2,238,277.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Francis Cogan sold 2,868 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $64.89, for a total transaction of $186,104.52. Following the sale, the director now directly owns 57,728 shares of the company’s stock, valued at approximately $3,745,969.92. The disclosure for this sale can be found here. Insiders have sold 15,884 shares of company stock valued at $1,054,459 in the last ninety days. 0.20% of the stock is currently owned by company insiders.

GILD opened at $66.92 on Friday. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $79.61. The business’s 50-day moving average price is $67.16. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. The company has a market capitalization of $85.32 billion, a PE ratio of 10.88, a price-to-earnings-growth ratio of 4.05 and a beta of 1.12.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business had revenue of $5.28 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the prior year, the business posted $1.48 earnings per share. Gilead Sciences’s revenue was up 3.8% compared to the same quarter last year. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.62 EPS for the current fiscal year.

GILD has been the topic of several research reports. Maxim Group set a $84.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. UBS Group upped their price objective on shares of L Brands from $26.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, April 10th. Goldman Sachs Group set a $27.00 price objective on shares of Melco Resorts & Entertainment and gave the company a “buy” rating in a report on Tuesday, May 28th. BMO Capital Markets set a $76.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Monday, July 15th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have issued a buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $81.09.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Straddles

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.